vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Forestar Group Inc. (FOR). Click either name above to swap in a different company.
Forestar Group Inc. is the larger business by last-quarter revenue ($273.0M vs $180.9M, roughly 1.5× AVANOS MEDICAL, INC.). Forestar Group Inc. runs the higher net margin — 5.6% vs -0.7%, a 6.4% gap on every dollar of revenue. On growth, Forestar Group Inc. posted the faster year-over-year revenue change (9.0% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-157.1M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -9.6%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
AVNS vs FOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $273.0M |
| Net Profit | $-1.3M | $15.4M |
| Gross Margin | 47.5% | 20.1% |
| Operating Margin | 1.4% | 7.6% |
| Net Margin | -0.7% | 5.6% |
| Revenue YoY | 0.7% | 9.0% |
| Net Profit YoY | 99.7% | -6.7% |
| EPS (diluted) | $-0.02 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $273.0M | ||
| Q3 25 | $177.8M | $670.5M | ||
| Q2 25 | $175.0M | $390.5M | ||
| Q1 25 | $167.5M | $351.0M | ||
| Q4 24 | $179.6M | $250.4M | ||
| Q3 24 | $170.4M | $551.3M | ||
| Q2 24 | $171.7M | $318.4M | ||
| Q1 24 | $166.1M | $333.8M |
| Q4 25 | $-1.3M | $15.4M | ||
| Q3 25 | $-1.4M | $86.9M | ||
| Q2 25 | $-76.8M | $32.9M | ||
| Q1 25 | $6.6M | $31.6M | ||
| Q4 24 | $-397.3M | $16.5M | ||
| Q3 24 | $4.3M | $81.5M | ||
| Q2 24 | $1.8M | $38.7M | ||
| Q1 24 | $-900.0K | $45.0M |
| Q4 25 | 47.5% | 20.1% | ||
| Q3 25 | 48.4% | 22.3% | ||
| Q2 25 | 52.6% | 20.4% | ||
| Q1 25 | 53.6% | 22.6% | ||
| Q4 24 | 54.6% | 22.0% | ||
| Q3 24 | 54.5% | 23.9% | ||
| Q2 24 | 55.7% | 22.5% | ||
| Q1 24 | 57.1% | 24.9% |
| Q4 25 | 1.4% | 7.6% | ||
| Q3 25 | 0.1% | 16.9% | ||
| Q2 25 | -42.6% | 11.2% | ||
| Q1 25 | 6.1% | 11.6% | ||
| Q4 24 | -233.0% | 8.7% | ||
| Q3 24 | 7.0% | 19.7% | ||
| Q2 24 | 3.7% | 16.2% | ||
| Q1 24 | 2.4% | 17.6% |
| Q4 25 | -0.7% | 5.6% | ||
| Q3 25 | -0.8% | 13.0% | ||
| Q2 25 | -43.9% | 8.4% | ||
| Q1 25 | 3.9% | 9.0% | ||
| Q4 24 | -221.2% | 6.6% | ||
| Q3 24 | 2.5% | 14.8% | ||
| Q2 24 | 1.0% | 12.2% | ||
| Q1 24 | -0.5% | 13.5% |
| Q4 25 | $-0.02 | $0.30 | ||
| Q3 25 | $-0.03 | $1.70 | ||
| Q2 25 | $-1.66 | $0.65 | ||
| Q1 25 | $0.14 | $0.62 | ||
| Q4 24 | $-8.64 | $0.32 | ||
| Q3 24 | $0.09 | $1.59 | ||
| Q2 24 | $0.04 | $0.76 | ||
| Q1 24 | $-0.02 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $211.7M |
| Total DebtLower is stronger | $90.3M | $793.2M |
| Stockholders' EquityBook value | $778.2M | $1.8B |
| Total Assets | $1.1B | $3.2B |
| Debt / EquityLower = less leverage | 0.12× | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $211.7M | ||
| Q3 25 | $70.5M | $379.2M | ||
| Q2 25 | $90.3M | $189.2M | ||
| Q1 25 | $97.0M | $174.3M | ||
| Q4 24 | $107.7M | $132.0M | ||
| Q3 24 | $89.0M | $481.2M | ||
| Q2 24 | $92.2M | $359.2M | ||
| Q1 24 | $75.8M | $416.2M |
| Q4 25 | $90.3M | $793.2M | ||
| Q3 25 | $93.4M | $802.7M | ||
| Q2 25 | $95.7M | $872.8M | ||
| Q1 25 | $98.0M | $872.5M | ||
| Q4 24 | $125.3M | $806.8M | ||
| Q3 24 | $152.6M | $706.4M | ||
| Q2 24 | $164.9M | $706.1M | ||
| Q1 24 | $167.2M | $705.7M |
| Q4 25 | $778.2M | $1.8B | ||
| Q3 25 | $778.0M | $1.8B | ||
| Q2 25 | $776.3M | $1.7B | ||
| Q1 25 | $839.4M | $1.6B | ||
| Q4 24 | $828.5M | $1.6B | ||
| Q3 24 | $1.2B | $1.6B | ||
| Q2 24 | $1.2B | $1.5B | ||
| Q1 24 | $1.2B | $1.5B |
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.1B | $3.1B | ||
| Q2 25 | $1.0B | $3.1B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $1.7B | $2.8B | ||
| Q2 24 | $1.7B | $2.7B | ||
| Q1 24 | $1.7B | $2.6B |
| Q4 25 | 0.12× | 0.44× | ||
| Q3 25 | 0.12× | 0.45× | ||
| Q2 25 | 0.12× | 0.52× | ||
| Q1 25 | 0.12× | 0.53× | ||
| Q4 24 | 0.15× | 0.50× | ||
| Q3 24 | 0.12× | 0.44× | ||
| Q2 24 | 0.13× | 0.47× | ||
| Q1 24 | 0.14× | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-157.0M |
| Free Cash FlowOCF − Capex | $21.3M | $-157.1M |
| FCF MarginFCF / Revenue | 11.8% | -57.5% |
| Capex IntensityCapex / Revenue | 3.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -10.19× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-157.0M | ||
| Q3 25 | $14.0M | $256.3M | ||
| Q2 25 | $6.8M | $15.8M | ||
| Q1 25 | $25.7M | $-19.8M | ||
| Q4 24 | $57.9M | $-450.0M | ||
| Q3 24 | $23.0M | $119.2M | ||
| Q2 24 | $27.8M | $-61.7M | ||
| Q1 24 | $-8.0M | $-59.2M |
| Q4 25 | $21.3M | $-157.1M | ||
| Q3 25 | $7.0M | $255.6M | ||
| Q2 25 | $-4.2M | $15.0M | ||
| Q1 25 | $19.0M | $-20.5M | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | $118.4M | ||
| Q2 24 | $21.9M | $-62.3M | ||
| Q1 24 | $-12.1M | $-59.8M |
| Q4 25 | 11.8% | -57.5% | ||
| Q3 25 | 3.9% | 38.1% | ||
| Q2 25 | -2.4% | 3.8% | ||
| Q1 25 | 11.3% | -5.8% | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | 21.5% | ||
| Q2 24 | 12.8% | -19.6% | ||
| Q1 24 | -7.3% | -17.9% |
| Q4 25 | 3.8% | 0.0% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.2% | ||
| Q4 24 | 2.7% | 0.0% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.2% | ||
| Q1 24 | 2.5% | 0.2% |
| Q4 25 | — | -10.19× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | 3.89× | -0.63× | ||
| Q4 24 | — | -27.27× | ||
| Q3 24 | 5.35× | 1.46× | ||
| Q2 24 | 15.44× | -1.59× | ||
| Q1 24 | — | -1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
